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Abstract
Introduction: Reproductive	scientists	have	postulated	various	risk	factors	for	lower	
birthweight	 following	 conventional	 gonadotropin‐stimulated	 in	 vitro	 fertilization	
compared	with	spontaneously	conceived	children:	parental	factors	(age,	health,	du‐
ration	of	subfertility	and	smoking	habits);	ovarian	stimulation;	laboratory	procedures;	
the	number	of	oocytes	retrieved	and	the	number	of	embryos	transferred.	Our	aim	
was	to	investigate	the	impact	of	gonadotropin	stimulation	and	serum	estradiol	level	
on	the	risk	of	a	newborn	being	small‐for‐gestational‐age.
Material and methods: We	 conducted	 a	 cohort	 study	 (2010‐2016)	 of	 singletons	
(n = 155)	born	either	after	conventional	gonadotropin‐stimulated	in	vitro	fertilization	
(using	≥150	IU/d	human	gonadotropin	for	stimulation)	or	after	natural	cycle	in	vitro	
fertilization	without	any	 stimulation.	We	analyzed	perinatal	outcomes	using	birth‐
weight	percentiles,	adjusted	for	gestational	age	and	sex.
Results: The	proportion	 of	 small‐for‐gestational‐age	was	11.8%	 following	 conven‐
tional	gonadotropin‐stimulated	 in	vitro	 fertilization	and	2.9%	after	natural	cycle	 in	
vitro	fertilization	(P =	0.058).	The	odds	of	small‐for‐gestational‐age	were	significantly	
higher	with	supraphysiological	estradiol	 levels	in	maternal	serum	on	ovulation	trig‐
ger	day	(unadjusted	odds	ratio	4.58;	95%	confidence	interval	1.35‐15.55;	P =	0.015).	
It	remained	significant	after	adjusting	for	maternal	height,	age	and	body	mass	index	
(adjusted	odds	ratio	3.83;	95%	confidence	interval	1.06‐13.82;	P =	0.041).
Conclusions: We	 found	 an	 associated	 risk	 of	 children	 being	 born	 small‐for‐gesta‐
tional‐age	after	conventional	gonadotropin‐stimulated	in	vitro	fertilization	compared	
with	 natural	 cycle	 in	 vitro	 fertilization.	 This	 higher	 risk	 is	 significantly	 associated	
with	 supraphysiological	 estradiol	 levels.	We	propose	a	 reduction	 in	 the	dosage	of	
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1  | INTRODUC TION
Birthweights	 in	 children	 born	 following	 conventional	 gonadotro‐
pin‐stimulated	 in	vitro	fertilization	 (c‐IVF)	and	fresh	embryo	trans‐
fer	are	shown	in	several	systematic	reviews	and	meta‐analyses1,2	to	
be	lower	than	birthweights	of	spontaneously	conceived	singletons.	
Various	risk	factors	were	postulated:3	parental	factors	(mainly	pre‐
existing	 diseases,	 duration	 of	 subfertility4	 and	 parental	 smoking);	
in	 vitro	 fertilization	 (IVF)	 laboratory	 procedures;5	 the	 number	 of	
oocytes	 retrieved;6	 and	 the	number	of	embryos	 transferred.	After	
the	 transfer	 of	 more	 than	 one	 embryo,	 fetal	 intrauterine	 growth	
restriction	may	be	a	consequence	of	vanishing	twins.2	Two	studies	
addressing	E2	levels	in	maternal	serum	at	ovulation	trigger	day	pos‐
tulated	a	dosage‐dependent	impact	of	gonadotropins	on	birthweight	
and	birthweight	percentile.7,8
Comparing	c‐IVF	with	natural	cycle	IVF	(NC‐IVF)	with	natural	
follicle	selection	and	without	the	use	of	gonadotropins	offers	an	
excellent	way	to	study	the	influence	of	hormones	on	obstetric	and	
perinatal	 outcomes.	 A	 recent	 systematic	 review	 found	 a	 signifi‐
cantly	higher	risk	of	low	birthweight	(LBW)	after	c‐IVF	(risk	ratio	
1.95;	95%	confidence	interval	[CI]	1.03‐3.67)	compared	with	mod‐
ified	IVF/NC‐IVF	therapy.9	Studies	included	in	the	review	focused	
on	birthweight	as	the	main	outcome	and	defined	LBW	as	<2500	g,	
without	 taking	 into	 consideration	 exact	 gestational	 age.6,10,11 
Using	birthweight	percentiles	adjusts	for	gestational	age	and	sex	
of	the	neonate.
Our	study	compares	birthweight	and	birthweight	percentiles	of	
c‐IVF	with	those	of	NC‐IVF	newborns.
2  | MATERIAL AND METHODS
2.1 | Study population
The	cohort	of	this	study	includes	women	treated	for	infertility	at	the	
Bern	University	Hospital,	Division	of	Gynecological	Endocrinology	
and	Reproductive	Medicine,	 Switzerland,	 from	2010	 to	 2016.	We	
retrieved	prospectively	 collected	data	and	prepared	 it	 for	analysis	
using	REDCap	electronic	data	(REDCap	8.5.19	Vaderbilt	University,	
Nashville,	 USA)	 capture	 tools	 hosted	 at	 the	 Clinical	 Trials	 Unit,	
University	of	Bern.
We	included	data	on	all	women	with	a	singleton	live	birth	after	
a	fresh	cleavage‐stage	embryo	transfer	who	underwent	either	c‐IVF	
or	NC‐IVF.	Women	with	a	regular	menstrual	cycle	chose	the	treat‐
ment	(NC‐IVF	or	c‐IVF)	as	per	their	preference.	We	did	not	include	
women	receiving	thawing	cycles	and	cycles	with	modified	IVF	treat‐
ment	(eg,	the	use	of	clomiphene	citrate	[CC]).	At	our	clinic,	we	offer	
treatments	with	modifying	drugs	such	as	CC	and	 low‐dose	human	
menopausal	gonadotropin	only	as	second‐line	options	after	several	
unsuccessful	 NC‐IVF	 treatments.	 Women	 receiving	 those	 treat‐
ments	 had	 previously	 several	 unsuccessful	 treatment	 cycles.	 Our	
aim	was	to	compare	two	clearly	distinct	approaches,	namely,	NC‐IVF	
without	 the	use	of	any	 stimulating	drugs	with	c‐IVF,	both	used	as	
first‐line	treatments.
2.2 | Data sources
We	 collected	 data	 on	 patient	 characteristics	 and	 reproductive	
treatment	from	medical	 records.	Chronic	disease	 included	asthma,	
Hashimoto's	thyroiditis	and	arterial	hypertension.	From	the	treating	
gynecologist	or	the	maternity	hospital	we	received	results	of	 later	
pregnancies,	delivery	reports	and	perinatal	 information	on	mother	
and	child.	We	considered	the	following	conditions	to	be	pregnancy	
complications:	 gestational	 hypertension,	 gestational	 diabetes,	 pla‐
cental	pathologies	(eg,	abnormal	placentation	such	as	placenta	previa	
or	placenta	accreta/increta),	antepartum	hemorrhage,	preterm	con‐
tractions,	preterm	rupture	of	membranes	and	fetal	growth	restric‐
tion.	We	calculated	fetal	weight	during	pregnancy	using	the	Hadlock	
formula.	From	the	available	fetal	growth	charts,	we	evaluated	utero‐
placental	 dysfunction	 (decrease	 in	 growth	 rate)	 and	 characteristic	
fetal	perfusion	changes	if	Doppler	ultrasound	was	available.	We	de‐
fined	according	to	the	TRUFFLE	study	for	fetal	growth	restriction12 
an	abnormal	umbilical	artery	Doppler	with	a	pulsatility	index	above	
the	95th	percentile	of	the	Doppler	reference	chart13	with	or	without	
reversed	or	absent	end‐diastolic	flow	as	pathologic.	We	calculated	
gestational	age	as	the	time	from	fertilization	at	the	day	of	follicular	
aspiration	 (FA)	 to	 delivery,	 plus	 14	 days.	We	used	 growths	 charts	
from	Voigt	&	Fenton14	to	determine	the	birthweight	percentile.	We	
defined	 a	 priori	 small‐for‐gestational‐age	 (SGA)	 as	 a	 birthweight	
gonadotropin	 to	 minimize	 the	 risk	 of	 small‐for‐gestational‐age	 and	 future	 health	
consequences.
K E Y W O R D S
gonadotropin,	high‐risk	pregnancy,	in	vitro	fertilization,	infertility,	pregnancy,	reproductive	
endocrinology
Key message
Supraphysiological	 serum	 estradiol	 levels	 under	 gonado‐
tropin	 stimulation	 in	 in	 vitro	 fertilization	 are	 associated	
with	 a	 higher	 incidence	 of	 children	 born	 small‐for‐gesta‐
tional‐age.	We	propose	a	 reduction	 in	gonadotropin	dos‐
age	to	minimize	potential	negative	health	consequences.
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≤5th	percentile.	This	reflects	a	degree	of	smallness	that	is	more	likely	
to	be	pathologic	rather	than	constitutional.15,16
2.3 | Conventional gonadotropin‐stimulated IVF
At	our	center,	we	perform	c‐IVF	as	either	a	short	agonist	protocol	or	
an	antagonist	protocol.	For	the	short	agonist	protocol,	we	use	trip‐
toreline	(gonadotropin‐releasing	hormone	agonist,	eg,	Decapeptyl®)	
and	150‐300	units	of	follicle‐stimulating	hormone	(eg,	Fostimon®)	
or	human	menopausal	gonadotropin	(Menopur®	or	Merional®)	for	
follicular	 stimulation,	 depending	 on	 age,	 Anti‐Müllerian	 hormone	
level	and	antral	 follicle	count.	For	 the	antagonist	protocol,	we	use	
human	 menopausal	 gonadotropin	 (150‐300	 units	 a	 day)	 for	 fol‐
licular	 stimulation	 and	 0.25	 mg	 cetrorelix	 (gonadotropin‐releasing	
hormone	antagonist,	eg,	Cetrotide®)	once	a	day,	beginning	at	stimu‐
lation	day	6	or	7.	We	monitor	cycles	using	ultrasound,	check	serum	
E2	 levels,	 and	 trigger	 ovulation	 with	 human	 choriogonadotropin	 
(eg,	Ovitrelle®)	when	the	size	of	the	leading	follicles	is	>17	mm.	We	
perform	FA	36	hours	later	under	conscious	sedation.
2.4 | Natural cycle IVF
We	perform	NC‐IVF	in	accordance	with	best	practice.17	We	perform	
follicle	monitoring	by	ultrasound	and	analysis	of	E2	and	luteinizing	
hormone	 (LH)	 concentrations,	 once	 preovulatory.	 When	 the	 fol‐
licular	diameter	 reaches	 at	 least	16	mm	and	 the	E2	 concentration	
is	 expected	 to	 be	 ≥800	 pmol/L,	 we	 administer	 a	 single	 dose	 of	
5000	IU	human	choriogonadotropin	as	a	trigger	and	FA	is	performed	
36	hours	later	without	anesthesia	using	a	19G	single	lumen	needle.	
In	the	event	of	 luteinizing	hormone‐surge	(>10	IU/L)	on	the	day	of	
human	choriogonadotropin	administration,	we	give	400	mg	ibupro‐
fen	every	8	hours	starting	a	maximum	of	48	hours	before	FA	until	
the	day	of	FA.	If	information	on	the	E2	concentration	on	ovulation	
trigger	day	is	not	available,	we	calculate	it	based	on	follicular	phase	
measurements.
For	both	types	of	treatment,	we	fertilize	the	mature	oocytes	by	
intracytoplasmic	 sperm	 injection,	 and	we	 culture	 a	 cleavage	 stage	
embryo.	For	the	assessment	of	embryo	quality,	we	use	ASEBIR	clas‐
sification18	based	on	the	number	of	cells,	the	heterogeneity	of	the	
cells,	and	the	fragmentation	rate	of	the	embryo.	We	transfer	the	em‐
bryo	at	cleavage	stage	with	a	soft	transfer	catheter	under	ultrasound	
surveillance.	Women	receive	luteal	phase	support	twice	a	day	after	
c‐IVF	with	 intravaginal	micronized	progesterone	 (eg,	Utrogestan®	
200	mg	or	Crinone®),	beginning	the	evening	of	the	day	of	FA	until	
the	12th	week	of	pregnancy.
2.5 | Statistical analyses
We	 performed	 statistical	 analysis	 using	 Fisher's	 exact	 test	 (SGA	 and	
LBW)	 or	 chi‐square	 test	 and	 Mantel‐Haenszel	 statistics	 for	 categori‐
cal	outcomes	and	linear	regression	for	continuous	outcomes.	As	seven	
women	with	two	IVF	children	each	were	included	in	the	dataset,	we	used	
 
NC‐IVF
%/SD
c‐IVF
%/SD P valuen = 70 n = 85
Maternal	age	(y) 34.23 3.76 34.57 4.15 0.598a
Maternal	height	(cm) 166.99 6.04 167.01 7.98 0.982a
Maternal	weight	(kg) 62.18 10.57 62.28 11.17 0.956a
Maternal	BMI	(kg/m2) 22.32 3.76 22.33 3.72 0.982a
Parity	(nulliparous) 52 74.29 72 84.71 0.107b
Smoking	before	pregnancy	(y/n) 7 10 15 17.65 0.248c
Smoking	during	pregnancy	(y/n) 0 0 4 4.71 0.141c
Chronic	disease	mother	(y/n) 12 17.14 19 22.40 0.420b
AMH	mother 21.52 22.30 24.79 21.32 0.358a
Indication	for	IVF
Male	factor 45 64.30 42 49.41 0.381c
Endometriosis 11 15.70 18 21.18
Tube	factor 3 4.30 5 5.88
PCO‐S 0 0.00 3 3.53
Idiopathic 10 14.29 15 17.65
Other 1 1.43 2 2.35
AMH,	Anti‐Müllerian	hormone;	BMI,	body	mass	index;	c‐IVF,	conventional	IVF;	cm,	centimeter;	IVF,	
in	vitro	fertilization;	kg,	kilogram;	m2,	square	meter	NC‐IVF,	natural	cycle	IVF;	PCO‐S,	polycystic	
ovary	syndrome;	SD,	standard	deviation;	y,	years;	y/n,	yes/no.
aLinear	regression.	
bChi‐square	test.	
cFisher's	exact	test.	
TA B L E  1  Patient	characteristics
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robust	standard	errors	controlling	for	clusters	in	the	regressions.	For	E2	
and	birth	percentile,	we	performed	multivariate	linear	regression,	and	for	
binary	 outcomes,	multivariate	 logistic	 regression.	We	 adjusted	 for	 the	
known	risk	factors:	maternal	age,	maternal	height	and	body	mass	index	
(BMI)	according	the	large	US	multicenter	study	from	Gardosi	&	Francis19 
and	controlled	for	multicollinearity	between	BMI	and	height.	For	parity	
(nulliparous/parous),	vanishing	twins	and	smoking	during	pregnancy	(yes/
no),	we	conducted	a	sensitivity	analysis	using	exact	 logistic	 regression.	
We	also	used	supraphysiological	E2	levels	(>10	000	pmol/L)	as	a	binary	
exposure.	The	E2	cut‐off	levels	in	previous	studies	ranged	between	9178	
and	12	665	pmol/L.7,8,20	We	considered	E2	>10	000	pmol/L	to	be	sup‐
raphysiological,	“because	this	E2	level	 is	higher	than	that	of	10	mature	
follicles	and	 lower	than	that	of	high‐risk	ovarian	hyperstimulation	syn‐
drome”8	and	it	comprises	median	and	mean	E2	levels	of	our	c‐IVF	pa‐
tients	(9590	pmol/L;	10	459	pmol/L).	We	present	odds	ratios	(OR)	and	
95%	CIs;	a	P	value	<0.05	is	considered	statistically	significant.
For	 statistical	 analysis,	 we	 used	 STATA	 statistical	 software	
Version	15	(Stata	Corporation,	College	Station,	Texas,	USA).
TA B L E  2  Stimulation	and	pregnancy	outcome	characteristics
 
NC‐IVF
%/SD
c‐IVF
%/SD P valueN = 70 N = 85
Stimulation
Nb	previous	transfers	(n) 1.94 1.74 1.62 0.88 0.138a
Day	of	retrieval	(d) 12.65 1.87 12.19 2.09 0.207a
Nb	oocytes	retrieved	(n) 1.01 0.12 8.20 4.73 <0.001a
Nb	of	embryos	transferred	(n) 1.01 0.12 2.01 0.36 <0.001a
Day	of	embryo	transfer	(d) 2.69 0.71 2.61 0.74 0.531a
Total	gonadotropin	dosage	(IU) — — 2322.77 758.41 —
Estradiol	at	trigger	day	(pmol/L) 1028.94 330.39 10 459.78 4552.12 <0.001a
Estradiol	at	trigger	day	(>10	000	pmol/L) 0 0 40 48.19 <0.001b
Endometrium	thickness	(mm) 8.59 1.75 9.86 2.37 <0.001a
Pregnancy
Duration	of	pregnancy	(wk.d) 39.2 1.52 38.94 2.51 0.451a
Pregnancy	hypertension	(n) 1 1.43 1 1.18 0.890c
Pregnancy	complication	(n) 16 22.56 26 30.59 0.309b
Induction	of	labor	(n) 22 35.48 28 34.57 0.909b
Very	preterm	birth	(<31	wk) 0 0 2 2.35 0.418c
Preterm	birth	(31‐36	wk) 5 7.14 5 5.88
Term	birth	(≥37	wk) 65 92.85 78 91.76
Infant	gender	female 36 51.43 34 40 0.155b
Infant	gender	male 34 48.57 51 60
Birthweight	(g) 3310.34 475.08 3218.25 704.38 0.352a
VLBW	(<1500	g) 0 0 3 3.53 0.231b
LBW	(1500‐2500	g) 2 2.86 4 4.71
Birthweight	≥2500	g	(n) 68 65.9 78 91.76
Birthweight	≥4000	g	(n) 6 8.57 9 10.59 0.673b
Percentile	(mean) 43.14 26.74 38.58 27.91 0.304a
SGA	(≤5th	percentile) 2 2.86 10 11.76 0.039b
Birthweight	≤10th	percentile	(n) 10 14.49 18 21.18 0.285b
Vanishing	twin	(n) 1 1.43 6 7.32 0.088c
Values	are	presented	as	means	with	standard	deviations	or	n	with	proportions	(%).
c‐IVF,	conventional	IVF;	d,	day;	g,	gram;	IU,	international	units;	IVF,	in	vitro	fertilization;	LBW,	low	birthweight;	mm,	millimeter;	NC‐IVF,	natural	cycle	
IVF;	n,	number;	pmol/L,	pico	mol	per	liter;	SD,	standard	deviation;	SGA,	small‐for‐gestational‐age;	VLBW,	very	low	birthweight;	wk,	week	of	gesta‐
tion;	wk.d,	week.day.
aLinear	regression.	
bChi‐square	test.	
cFisher's	exact	test.	
Bold	values	are	statistically	significant.
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2.6 | Ethics approval
The	 cantonal	 ethical	 committee	 of	 Bern	 (KEK	 Bern,	 397/15),	
Switzerland,	approved	the	study	on	26	January	2016.
3  | RESULTS
We	 identified	643	pregnancies	 from	 the	2010‐2016	period.	We	ex‐
cluded	159	births	after	frozen	embryo	transfer.	Of	484	women	who	
underwent	a	fresh	embryo	transfer,	one	woman	was	lost	to	follow	up,	
188	had	a	miscarriage	and	26	had	a	multiple	pregnancy.	We	excluded	
114	singleton	deliveries	because	of	modifications	(see	Study	popula‐
tion	2.1.).	These	resulted	in	155	singleton	deliveries	in	the	analysis:	85	
conceived	after	c‐IVF	and	70	after	a	NC‐IVF	treatment.	Twelve	women	
did	not	consent	to	further	data	collection	associated	with	their	child.
3.1 | Study population characteristics
Within	the	c‐IVF	group,	21	had	an	agonist	protocol	and	64	had	an	an‐
tagonist	protocol.	See	Table	1	for	patient	and	treatment	characteristics.	
We	could	not	find	a	significant	difference	in	age,	BMI,	parity	or	smoking	
between	the	two	groups.	Prevalence	of	chronic	diseases	was	compara‐
ble	between	c‐IVF	and	NC‐IVF	(22.40%	vs	17.14%;	P =	0.420).
We	 found	 that	 stimulation	 characteristics	 were	 significantly	
higher	 in	 c‐IVF	but	 the	number	of	 previous	embryo	 transfers	was	
similar	(Table	2).
3.2 | Pregnancy characteristics
We	note	 that	 there	were	no	differences	 in	pregnancy	 complica‐
tions,	 eg,	 gestational	 hypertension,	 between	 the	 two	 groups	
(Table	2).	The	rate	of	preterm	births	(<37	gestational	weeks)	was	
8.24%	(n = 7)	 in	the	c‐IVF	group	and	7.14%	(n = 5)	 in	the	NC‐IVF	
(P = 1.000)	group.
The	 overall	 mean	 birthweight	 and	 percentile	 were	 3218	 g	
(±704	g),	38.6th	percentile	for	c‐IVF	and	3310	g	(±475),	43.1st	per‐
centile	for	NC‐IVF,	respectively,	P =	0.352.	The	proportion	of	LBW	
was	8.24%	(n = 7)	 in	c‐IVF	and	2.90%	(n = 2)	in	NC‐IVF,	P =	0.188,	
whereas	the	 incidence	of	birthweight	>4000	g	was	10.59%	(n = 9)	
in	the	c‐IVF	group	and	8.57%	(n	=	6)	in	the	NC‐IVF	group,	P = 0.673.
3.3 | Small‐for‐gestational‐age
More	children	were	born	as	SGA	following	c‐IVF	(11.76%,	n = 10; 4 
male,	6	female)	than	following	NC‐IVF	(2.86%,	n = 2;	both	male),	with	
an	odds	ratio	of	4.53	for	an	SGA	child	in	a	logistic	regression	(95%	
CI	0.95‐21.61,	P =	0.058,	Figure	1).	After	we	adjusted	for	confound‐
ing	 factors	 such	 as	 maternal	 age,	 height	 and	 BMI,	 the	 odds	 ratio	
was	somewhat	attenuated	(OR	4.23;	95%	CI	0.87‐20.41;	P =	0.073,	
Model	I	in	Table	3).	If	we	additionally	adjust	for	the	E2	level,	the	odds	
ratio	is	further	reduced	to	1.01	(95%	CI	0.87‐1.19,	P	=	0.971,	Model	
III	in	Table	3).
3.4 | Supraphysiological estradiol level
The	 influence	 on	 birthweight	 percentile	 of	 an	 E2	 level	 of	
>10	 000	 pmol/L	 on	 ovulation	 trigger	 day	 was	 significant	 in	 the	
crude	analysis	(unadjusted	OR	4.58;	95%	CI	1.35‐15.55;	P =	0.015)	
and	remained	significant	when	adjusted	(adjusted	OR	3.83;	95%	CI	
1.06‐13.82;	P =	0.041)	(Model	II	in	Table	3;	Figure	2).	The	sensitivity	
analysis	regarding	parity,	smoking	and	vanishing	twins	showed	very	
similar	odds	 ratios	 for	 stimulation	 schemes	 in	crude	and	adjusted	
analyses	(OR	1.45	vs	1.41,	1.48	and	1.41,	respectively).	 In	the	lin‐
ear	 regression,	 the	 association	 between	E2	 level	 and	 birthweight	
and	birthweight	percentile	is	modest.	Birthweights	and	birthweight	
F I G U R E  1  Boxplot	of	birthweight	
percentiles	of	conventional	gonadotropin‐
stimulated	in	vitro	fertilization	(c‐IVF)	
vs	natural	cycle	in	vitro	fertilization	
(NC‐IVF)	[Color	figure	can	be	viewed	at	
wileyonlinelibrary.com]
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percentiles	are	lower	with	higher	E2	levels	on	ovulation	trigger	day.	
The	adjusted	linear	regression	of	NC‐IVF	children	shows	a	signifi‐
cant	 decrease	of	 three	 percentiles	 by	 E2	 increase	of	 100	pmol/L	
at	ovulation	trigger	day	(CI	−4.61	to	−1.39;	P <0.001,	Figure	3).	For	
c‐IVF	this	is	a	decrease	of	0.05	percentiles	with	an	E2	increase	of	
100	pmol/L	(CI	−0.02	to	0.18;	P =	0.451,	Figure	4).	The	effect	of	the	
stimulation	scheme	was	completely	leveled	out	when	we	controlled	
for	the	E2	level.
3.5 | Doppler analysis
We	 obtained	 complete	 pregnancy	 records	 for	 8	 of	 12	 children	
born	as	SGA.	The	evaluation	of	their	fetal	growth	charts	showed	
four	(42%;	1	NC‐IVF,	3	c‐IVF)	cases	with	utero‐placental	dysfunc‐
tion	(late	flattening	growth,	pathological	Doppler	analysis)	and	one	
case	with	a	placental	 infarction	 (c‐IVF)	and	pathological	Doppler	
analysis.	We	did	 not	 have	 comparable	 information	 for	 the	 other	
four	 cases	 because	 the	 treating	 gynecologist	 did	 not	 perform	 a	
Doppler	measurement.
4  | DISCUSSION
This	 cohort	 study	 of	 singletons	 conceived	 after	 fresh	 IVF	 therapy	
focuses	 on	 the	 effect	 of	 ovarian	 stimulation	 on	 birth	 outcomes.	
Overall,	gonadotropins	seem	to	reduce	birthweight	and	birthweight	
TA B L E  3  Multilevel	logistic	regression	for	small‐for‐gestational‐age
N = 155
Unadjusted OR (95% 
CI) (for each determi‐
nant individually) P value
Model I
P value
Model II
P value
Model III
P value
Adjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Stimulation	(c‐IVF) 4.53	(0.95‐21.61) 0.058 4.23	(0.87‐20.41) 0.073   1.05	(0.87‐1.17) 0.971
Mother	age	
(continuous)
1.01	(0.89‐1.17) 0.820 0.99	(0.88‐1.13) 0.952 1.01 
(0.87‐1.19)
0.811 1.01	(0.87‐1.17) 0.901
Mother	age	(>36	y) 0.98	(0.28‐3.48) 0.987       
Mother	height	
(continuous)
0.88	(0.79‐0.99) 0.026 0.89	(0.81‐0.98) 0.019 0.90 
(0.81‐0.99)
0.042 0.90	(0.81‐.99) 0.032
Mother	height	
(<160	cm)
5.46	(1.42‐20.92) 0.013       
Mother	BMI	
(continuous)
0.99	(0.83‐1.18) 0.944 0.96	(0.78‐1.17) 0.668 0.96 
(0.74‐1.24)
0.753 0.98	(0.77‐1.24) 0.847
Mother	BMI	(<20	m2) 1.24	(0.35‐4.40) 0.735       
E2	level	(continuous) 1	(1.00‐1.00) 0.003     1.00 
(1.00‐1.00)
0.127
E2	level	on	trigger	day	
(<10	000	vs	≥10	000)
4.58	(1.35‐15.55) 0.015   3.83 
(1.06‐13.82)
0.041   
Nulliparous	(0	vs	≥1) 3.81a,b 0.188       
Smoking	during	preg‐
nancy	(y/n)
0.99	(0‐1.04)	b 0.984       
Vanishing	twin	(y/n) 2.25	(0.24‐20.73) 0.474       
Pregnancy	complica‐
tion	(y/n)
2.88	(0.87‐9.6) 0.083       
Pregnancy	hyperten‐
sion	(y/n)
12.90	(0.75‐222.94) 0.078       
Induction	of	labor	(y/n) 0.92	(0.26‐3.26) 0.902       
LBW	(<2500	vs	
≥2500	g)
24.64	(5.4‐113.98) <0.001       
Model	I:	adjusted	multivariate	logistic	regressions	with	SGA	as	outcome	and	stimulation	as	exposure	adjusted	for	age,	height	and	BMI	as	continuous	
variables.
Model	II:	adjusted	multivariate	logistic	regression	with	SGA	as	outcome	and	supraphysiological	E2	level	as	exposure	adjusted	for	age,	height	and	BMI	
as	continuous	variables.
Model	III:	adjusted	multivariate	logistic	regression	with	SGA	as	outcome	and	stimulation	as	exposure	adjusted	for	E2,	age,	height	and	BMI	as	continu‐
ous variables.
c‐IVF,	conventional	IVF;	cm,	centimeters;	g,	gram;	IVF,	in	vitro	fertilization;	NC‐IVF,	natural	cycle	IVF;	y,	years;	n,	number;	m2,	square	meter;	OR,	odds	
ratio;	pmol/L,	picomol	per	liter;	y/n,	yes/no;	95%	CI,	95%	confidence	interval.
aMedian	unbiased	estimate.	
bExact	logistic	regression.	
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percentiles,	 especially	when	 used	 for	 ovarian	 stimulation	 reaching	
supraphysiological	E2	levels	on	ovulation	trigger	day.	The	two	main	
findings	of	our	study	are:	(1)	the	risk	associated	of	children	being	born	
SGA	after	c‐IVF	compared	with	NC‐IVF;	and	 (2)	 the	association	of	
SGA	children	with	supraphysiological	E2	levels	on	ovulation	trigger	
day.	After	adjusting	for	established	risk	factors,	the	supraphysiologi‐
cal	E2	level	in	particular	was	determined	to	be	a	relevant	risk	factor	
for	SGA;	this	even	levels	out	completely	the	effect	of	the	stimulation	
scheme.
These	 results	 contribute	 to	 the	 important	 debate	 on	 whether	
ovarian	stimulation	poses	a	risk	for	SGA	or	LBW	and	to	the	health	
of	the	 IVF	children	 later	 in	 life	and	what	could	be	the	determining	
factors.
For	 children	 conceived	 by	 NC‐IVF,	 the	 incidence	 of	 SGA	 was	
analyzed	only	once,	 by	Mak	et	 al.10	 They	 compared	190	 singletons	
after	NC‐IVF	with	174	after	c‐IVF.	In	both	groups,	the	percentage	of	
preterm	births	was	exceptionally	high	(31.5%	vs	42%)	but	the	differ‐
ence	in	birthweights	was	significant	(NC‐IVF	3426	±	420	g	vs	c‐IVF	
3273	±	574	g,	P =	0.01).	Because	of	the	high	rate	of	preterm	neonates	
(36.3%),	this	population	is	not	completely	comparable	to	ours	(7.74%	
preterm	only).
Our	 results	 suggest	 that	 the	 stimulation	 is	detrimental	 if	 a	 su‐
praphysiological	 estradiol	 level	 is	 reached.	 Measures	 of	 intensive	
ovarian	 hyperstimulation,	 such	 as	 supraphysiological	 E2	 levels	 on	
ovulation	 trigger	 day7,20	 and	 a	 high	number	of	 oocytes	 retrieved,6 
have	been	identified	previously	as	independent	risk	factors	for	lower	
F I G U R E  2  Boxplot	of	birthweight	
percentiles	estradiol	(E2)	level	
<10	000	pmol/L	vs	≥10	000	pmol/L	
E2	level	[Color	figure	can	be	viewed	at	
wileyonlinelibrary.com]
F I G U R E  3  Birthweight	percentile	with	
higher	estradiol	(E2)	level	(in	maternal	
serum,	pmol/L)	on	ovulation	trigger	day	
in	natural	cycle	in	vitro	fertilization	[Color	
figure	can	be	viewed	at	wileyonlinelibrary.
com]
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birthweight	in	IVF	therapy.	Supraphysiological	E2	levels	are	also	as‐
sociated	with	 a	 higher	 risk	 of	 preeclampsia	 (18).	Our	 results	 even	
suggest	that	the	effect	of	E2	level	on	ovulation	trigger	day	outweighs	
the	choice	of	stimulation	scheme	and	the	amount	of	gonadotropins	
used.	 It	would	 be	 necessary	 to	 predict	more	 accurately	 individual	
stimulation	responses	and	the	E2	levels.
The	strength	of	our	study	is	the	equal	access	of	all	couples	to	both	
treatments	in	our	center,	which	reduces	(but	does	not	eliminate)	selec‐
tion	bias.	The	only	difference	between	the	groups	is	the	use	of	gonad‐
otropins	for	stimulation,	resulting	in	higher	serum	E2	levels,	a	higher	
number	of	oocytes	retrieved,	and	a	higher	number	of	embryos	trans‐
ferred	within	the	c‐IVF	group,	also	resulting	in	more	vanishing	twins.	
All	other	factors,	such	as	laboratory	conditions	and	the	staff	providing	
the	treatment,	were	similar	for	the	two	groups.	With	regard	to	parental	
health	and	underlying	subfertility	as	well	as	manipulation	and	culture	
of	 the	embryos,	we	would	not	 expect	 any	differences	between	 the	
two	groups.	Additionally,	the	use	of	birthweight	percentiles	increases	
the	prognostic	value	of	this	particular	parameter	compared	with	birth‐
weight	alone.
A	limitation	of	our	study	is	the	small	sample	size.	We	recruited	
within	 our	 center	 to	 increase	 comparability	 between	 both	 groups	
and	we	were	able	to	have	access	to	complete	treatment	data	for	all	
cases.	A	prospective	design	with	random	allocation	of	fertility	treat‐
ment	is	not	possible	in	Switzerland	because	the	couple	completely	
pays	for	fertility	treatment	themselves.
Further	 factors	may	affect	our	 results;	when	two	or	more	em‐
bryos	 are	 transferred	 and	 one	 gestation	 vanishes,	 the	 remaining	
fetus	is	physiologically	seen	as	a	twin.	Pinborg	showed	its	associa‐
tion	with	LBW	and	SGA	(2).	In	our	population,	we	had	six	vanishing	
twins	in	the	c‐IVF	group	and	one	in	the	NC‐IVF	group;	this	did	not	
affect	the	incidence	of	SGA.
Animal	models	showed	that	high	serum	E2	 levels	suppress	 the	
extra	 villous	 trophoblast	 vascular	 endothelial	 growth	 factor	 and	
hinder	 uterine	 spiral	 artery	 invasion	 into	 the	 placenta.21	 A	 supra‐
physiological	 E2	 environment,	 such	 as	 in	 gonadotropin‐stimulated	
cycles,	may	result	in	an	edematous	endometrium	impairing	tropho‐
blast	differentiation	and	abnormal	placentation,	compared	with	the	
physiologic	 endometrium	 conditions	 in	NC‐IVF.22	We	 hypothesize	
that	these	mechanisms	might	be	one	reason	for	the	increased	inci‐
dence	of	SGA	children	after	gonadotropin‐stimulated	IVF	therapies	
compared	with	spontaneously	conceived	children.
In	1998,	Barker	linked	maternal	nutrition	during	the	preimplanta‐
tion	period	to	intrauterine	growth;	his	work	showed	that	intrauterine‐
affected	individuals	are	at	greater	risk	of	developing	coronary	heart	
disease,	 hypertension	 and	 diabetes;	 this	 is	 known	 as	 the	 “Barker's	
hypothesis”	 or	 the	 “developmental	 origins	 of	 health	 and	 disease	
theory”.23
IVF	offspring	have	not	yet	reached	late	adult	life.	Multiple	stud‐
ies	 suggest	 that	 c‐IVF	children,	 especially	with	 an	associated	 fetal	
growth	 restriction,24	 may	 face	 health	 issues	 later	 in	 life,	 such	 as	
reduced	 insulin	 sensitivity,	 cardiovascular	 dysfunction	 and	 higher	
blood	pressure	at	school	age.25,26	Larger	prospective	cohort	studies	
should	investigate	further	the	effects	of	gonadotropins	and	supra‐
physiological	E2	levels	on	intrauterine	growth	and	the	health	of	IVF	
children.
The	extent	 to	which	 gonadotropin	 stimulation	 is	 associated	
with	 LBW	 and	 SGA,	 and	 consequently	 their	 possible	 negative	
health	 conditions,	 is	 still	 not	 clear.	 However,	 while	 we	 cannot	
alter	 many	 factors	 in	 IVF	 therapy	 to	 achieve	 acceptable	 preg‐
nancy	 outcomes,	 we	 can	 reduce	 the	 use	 of	 gonadotropin	 and	
the	dosage	when	it	is	used.	Furthermore,	the	risk	of	SGA	can	be	
reduced	 by	 frozen	 embryo	 transfer	 cycles,	 but	 there	 instead	 a	
higher	risk	of	 large‐for‐gestational‐age	 (LGA),27	and	preeclamp‐
sia28	 has	 been	 described	 recently.	 In	 NC‐IVF,	 the	 serum	 E2	
milieu	 remains	 within	 physiologic	 limits,17,29 whereas gonado‐
tropin	stimulation	in	c‐IVF	alters	 it.	NC‐IVF	as	well	as	 low‐dose	
F I G U R E  4  Birthweight	percentile	with	
higher	estradiol	(E2)	level	(in	maternal	
serum,	pmol/L)	on	ovulation	trigger	day	
in	conventional	gonadotropin‐stimulated	
in	vitro	fertilization	[Color	figure	can	be	
viewed	at	wileyonlinelibrary.com]
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stimulation‐IVF	may	be	options	to	reduce	the	risk	of	supraphysi‐
ological	E2	levels	and	consequently	LBW	and	SGA.	Several	stud‐
ies	that	 looked	at	mild	stimulation	found	similar	pregnancy	and	
live	birth	rates,	better	quality	oocytes	and	less	adverse	effects	of	
the	stimulation.	Although	Baart	et	al.30	found	fewer	aneuploidy	
and	mosaic	embryos	following	mild	stimulation,	there	is	still	not	
much	 known	 about	 perinatal	 outcome	 including	 the	 effect	 on	
LBW	and	SGA.
5  | CONCLUSION
Lower	 stimulation	 dosages	 are	 associated	with	 lower	 E2	 levels	 at	
ovulation	trigger	day.	There	is	consecutively	a	lower	risk	of	ovarian	
hyperstimulation	 syndrome	and	we	assume	 lower	associated	peri‐
natal	health	risks.	Even	if	the	effect	of	gonadotropins	on	the	risk	for	
SGA	 is	 not	 yet	 fully	 proven,	we	 advise	 reproductive	 specialists	 to	
consider	natural	cycle	or	low‐dose	ovarian	stimulation.
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